- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04692324
Cerebrospinal Fluid Biomarkers for Brain Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. To collect cerebrospinal fluid (CSF) samples that can provide a resource to the research community for biomarker discovery in patients with gliomas.
SECONDARY OBJECTIVE:
I. Evaluate the feasibility of serial CSF sampling from patients with brain tumors for longitudinal evaluation of tumor biomarkers.
OUTLINE:
Patients undergo collection of CSF samples via lumbar puncture at least 2 times. Patients may undergo additional collection of additional CSF samples if they choose.
After completion of study treatment, patients are followed up periodically.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Clinical Trials Referral Office
- Phone Number: 855-776-0015
- Email: mayocliniccancerstudies@mayo.edu
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic in Rochester
-
Contact:
- Clinical Trials Referral Office
- Phone Number: 855-776-0015
- Email: mayocliniccancerstudies@mayo.edu
-
Principal Investigator:
- Terence C. Burns, M.D., Ph.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Any evidence of neoplasm involving the central nervous system (CNS) or its adjacent structures in contact with CSF. Such lesions may include but are not limited to intra-axial or extra-axial lesions, which could be benign, malignant or as yet undefined, involving the brain, spine, meninges, nerves, or vasculature or supporting structures
- Subjects must be 18 years of age or older
Exclusion Criteria:
- Patients who are under 18 years of age or are a member of a vulnerable population will be excluded from this study
- Pregnant women or women who may be pregnant are specifically excluded from study participation
- Exception will be granted for patients with diminished capacity to consent if a legally authorized representative is available
- Patients without clinical or radiographic evidence of a potentially neoplastic CNS lesion will be excluded
- Patients with an inability or unwillingness of individual or legal guardian/representative to give written informed consent will be excluded
- Any patient for whom a clinical contraindication exists to the intended route of CSF access will be excluded. For example, a patient with a large posterior fossa mass lesion at risk of herniation, or a patient with coagulopathy, or other contraindication to lumbar puncture would not be eligible to participate via use of lumbar puncture for CSF access
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Basic science (biospecimen collection)
Patients undergo collection of CSF samples via lumbar puncture at least 2 times.
Patients may undergo additional collection of additional CSF samples if they choose.
|
Ancillary studies
Review of medical records
Undergo collection of CSF samples
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Collection cerebrospinal fluid (CSF) samples that can provide a resource to the research community for biomarker discovery
Time Frame: Up to study completion
|
Up to study completion
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Feasibility of serial cerebrospinal fluid (CSF) sampling
Time Frame: Up to study completion
|
Up to study completion
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Terence C. Burns, M.D., Ph.D., Mayo Clinic in Rochester
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20-008832 (Other Identifier: Mayo Clinic in Rochester)
- P30CA015083 (U.S. NIH Grant/Contract)
- NCI-2021-02765 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- R61NS122096 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Central Nervous System Neoplasm
-
Mayo ClinicRecruitingMalignant Central Nervous System NeoplasmUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Not yet recruitingMalignant Central Nervous System NeoplasmUnited States
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedMalignant Central Nervous System NeoplasmUnited States
-
Daniel M. SpielmanNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedMalignant Central Nervous System Neoplasm | Metastatic Malignant Neoplasm in the Central Nervous SystemUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRefractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central Nervous System Neoplasm | Childhood Solid NeoplasmUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)Active, not recruitingRefractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central Nervous System Neoplasm | Childhood Solid NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedCentral Nervous System Neoplasm | Solid NeoplasmUnited States, Canada
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingGlioma | Metastatic Malignant Solid Neoplasm | Central Nervous System Neoplasm | Metastatic Malignant Neoplasm in the Central Nervous SystemUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingMalignant Central Nervous System Neoplasm | Primary Central Nervous System NeoplasmUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedMetastatic Malignant Neoplasm in the Brain | Recurrent Brain Neoplasm | Central Nervous System Neoplasm | Localized Brain NeoplasmUnited States
Clinical Trials on Survey Administration
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Boston UniversityNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHepatocellular CarcinomaUnited States
-
Thomas Jefferson UniversityRecruitingMalignant Head and Neck NeoplasmUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingAcute Lymphoblastic LeukemiaUnited States
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)RecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Advanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | COVID-19 Infection | Recurrent Hematologic MalignancyUnited States
-
Thomas Jefferson UniversityNational Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States